 | Up a level |
Journal Article
Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey 
ORCID: 0000-0002-2603-7296, Santoro, Armando ORCID: 0000-0003-1709-9492, Sutradhar, Santosh, Li, Siyu, Szczudlo, Tomasz, Yovine, Alejandro and Shaw, Alice T.
(2016).
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Lancet Oncol., 17 (4).
S. 452 - 464.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
Shaw, Alice, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraldes, Margarida, Sen, Paramita, Boral, Anthony J., Yovine, Alejandro and Kim, Dong-Wan
(2014).
CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL.
Neuro-Oncology, 16.
CARY:
OXFORD UNIV PRESS INC.
ISSN 1523-5866